
Vivek Subbiah/LinkedIn
Jun 25, 2025, 08:29
Vivek Subbiah Highlights STELLAR-303 Trial Results for Zanzalintinib Combo in mCRC
Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on X:
“Press release Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer | Exelixis, Inc.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 25, 2025, 07:56
Jun 25, 2025, 07:49
Jun 25, 2025, 07:33